Is Mainz Biomed NV halal to invest in?

According to Musaffa's Shariah screening methodology, Mainz Biomed NV (MYNZ) is currently classified as NOT HALAL as of December 2025. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Mainz Biomed NV a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Mainz Biomed NV using these criteria to determine its compliance status.

Can Muslims buy shares of Mainz Biomed NV?

Muslim investors may consider investing in Mainz Biomed NV if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Mainz Biomed NV classified as NOT HALAL?

Musaffa determines the Shariah status of Mainz Biomed NV by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Mainz Biomed NV updated?

The Shariah compliance status of Mainz Biomed NV may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Mainz Biomed NV become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Mainz Biomed NV?

You can check the latest Shariah compliance status of Mainz Biomed NV on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

MYNZ Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: December 04, 2025

Report Source: 2025 2nd Quarter Report

Mainz Biomed NV. Stock Analysis MYNZ

United States Health Care Nano Cap Report: Q2, 2025

Mainz Biomed NV is a molecular genetics cancer diagnostic company. The company is headquartered in Mainz, Hessen and currently employs 19 full-time employees. The company went IPO on 2021-11-04. The firm operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The firm competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.

Key Statistics of Mainz Biomed NV (MYNZ)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$0.74$0.83

Today's Open

$0.80

Volume

81.09M

P/E Ratio (TTM)

52 Week Range

$0.55$5.54

Market Cap

7.35M

Avg. Volume

39.20M

Dividend Yield

Financial Metrics & Statements of Mainz Biomed NV (MYNZ)

FAQ's for Mainz Biomed NV (MYNZ)

According to Musaffa’s Shariah screening methodology, Mainz Biomed NV (MYNZ) is currently classified as NOT HALAL as of December 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.